Personalized Medicine in Diabetes: Regulatory Considerations

AUTOR(ES)

Harper, Courtney C.

FONTE

Diabetes Technology Society

RESUMO

Personalized medicine has become a topic of great interest because of its potential to improve patient care and optimize therapeutic strategy. The U.S. Food and Drug Administration (FDA) is interested in promoting personalized medicine, whenever appropriate, to protect and promote the public health. The ability to better diagnose, screen, and manage patients with diabetes in order to individualize care should lead to better health outcomes and a large benefit to public health. This article describes FDA regulatory considerations for devices intended for use as personalized medicine tools for the diagnosis and treatment of patients with diabetes.

Documentos Relacionados

• The Personalized Medicine for Diabetes Meeting Summary Report
• Pharmacogenetics for Type 2 Diabetes: Practical Considerations for Study Design
• Circulating Biomarkers of Glycemia in Diabetes Management and Implications for Personalized Medicine
• The Case for Personalized Medicine
• Artificial intelligence, radiology, precision medicine, and personalized medicine